Frontage Holdings Corporation (FGHQF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Frontage Holdings Corporation $0.14, price $0.18, upside -20.0%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Frontage Holdings Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.1010 – $0.8000 · fair‑value band $0.1000 – $0.1800 · the $0.1750 price screens above the $0.1400 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Frontage Holdings in your weekly email
Every Wednesday you see whether Frontage Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies.
Show more
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such as pharmacology, medical writing, and regulatory support. In addition, it offers pharmaceutical product development services, including intermediate and active pharmaceutical ingredient (API) synthesis, process and formulation development, and clinical trial material manufacturing. Further, the company provides laboratory testing services, such as bioanalysis, biomarkers, genomics, chemistry, manufacturing and controls ("CMC") analytical testing, and central laboratory services. It operates in the United States, Canada, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was founded in 2001 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation operates as a subsidiary of Hongkong Tigermed Consulting Co., ltd.
Stock analysis
Frontage Holdings Corporation (FGHQF) currently trades at $0.1750, while our model-based Fair Value estimate is $0.1400, 20.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.1900 per share, and 8 of the 24 models we run sit above the $0.1750 price.
Bear case: the Earnings-Based group reads lowest at $0.0400, and 16 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.1000 (bear) to $0.1800 (bull), the price of $0.1750 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Frontage Holdings Corporation reported revenue of $257M in FY2025 versus $184M in FY2021, a compound +8.7%/yr. Reported net income was $6.8M in FY2025, compounding −22.1%/yr from FY2021.
Key figures
Market cap $355M · P/S ratio 0.87 · Net margin 2.6% · Return on equity 2.0% · Return on assets (EBIT) 3.8% · Operating margin 6.8% · Revenue (TTM) $257M · Revenue growth (YoY) +2.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 59% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −20%, FGHQF screens richer than that median.
Fair Value models
Bear $0.1000Fair Value $0.1400Bull $0.1800
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.4%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.3%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−3.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 6%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +1.3% a year for the price.
Compare Frontage Holdings Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 10/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score59 · Top 25%
Fair Value upside−1.7% · Above median
Profitability
Return on equity (TTM)2.0% · Above median
Return on assets1.8% · Above median
Net margin (TTM)2.7% · Below median
Operating margin (TTM)6.8% · Above median
Growth and dividend
Revenue growth2.9% · Above median
Balance sheet
Debt / equity0.08× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Frontage Holdings Corporation (FGHQF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.1400 versus the last price from Sep 25, 2026 of $0.1750, about −20% upside (overvalued).
What is the fair value of FGHQF?
Our model-based fair value for Frontage Holdings Corporation is $0.1400 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.1750.
What is the quality score of FGHQF?
Frontage Holdings Corporation has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Frontage Holdings Corporation (FGHQF)?
Our model-based price target is the fair value of $0.1400 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $0.1000, optimistic scenario $0.1800. It is a calculation from audited fundamentals, not an analyst target.
What is the Frontage Holdings Corporation stock forecast for 2026?
Our models put fair value at $0.1400, about −20% upside versus the last price from Sep 25, 2026 of $0.1750 (overvalued). Cautious scenario $0.1000, optimistic scenario $0.1800. The calculation is refreshed regularly with new filings.
What is the revenue of Frontage Holdings Corporation (FGHQF)?
Frontage Holdings Corporation reported trailing-twelve-month revenue of about $257M (latest available figure, as of Sep 24, 2026).
What growth is priced into Frontage Holdings Corporation (FGHQF)?
For today's price to be fair in a discounted-cash-flow model, Frontage Holdings Corporation would have to grow free cash flow by +3.8 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of FGHQF use?
Our models discount Frontage Holdings Corporation at 11.2 %: a base by market capitalisation (micro), damped by beta 0.15, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Frontage Holdings Corporation that is +3.8 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Frontage Holdings Corporation (FGHQF) delivered so far?
Over the past 5 years revenue at Frontage Holdings Corporation grew +15.4 % a year. The price currently implies +3.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Frontage Holdings Corporation (FGHQF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Frontage Holdings Corporation (+3.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Frontage Holdings Corporation (FGHQF)?
The free-cash-flow yield on the price is 9.09 %: that much free cash flow Frontage Holdings Corporation produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Frontage Holdings Corporation (FGHQF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Frontage Holdings Corporation it is $0.1400 per share (as of Sep 24, 2026), against a price of $0.1750. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Frontage Holdings Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, FGHQF trades above its calculated fair value: price $0.1750, fair value $0.1400, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FGHQF?
No. The price is what the market pays today ($0.1750); the fair value is what the company's own numbers justify ($0.1400). For Frontage Holdings Corporation the two are $0.0350 per share apart. That gap is exactly why we show both numbers side by side.
How much is Frontage Holdings Corporation worth?
The market values Frontage Holdings Corporation at about $355M (market capitalisation, as of Sep 24, 2026). Per share that is $0.1750; our models calculate a fair value of $0.1400 per share.
What do the bullish and bearish scenarios say about FGHQF?
Our models span a range for Frontage Holdings Corporation: cautious scenario $0.1000, base $0.1400, optimistic $0.1800 per share (as of Sep 24, 2026, price $0.1750). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Frontage Holdings Corporation (FGHQF)?
Balance-sheet figures for Frontage Holdings Corporation (as of Sep 24, 2026): return on equity 2.0%, debt of 0.08 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is FGHQF from its 52-week high?
Frontage Holdings Corporation trades at $0.1750, about 13% below its 52-week high of $0.2001 and 59% above the low of $0.1100 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1400 is for.
Which stocks are comparable to Frontage Holdings Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Frontage Holdings Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price $0.1750, calculated fair value $0.1400 (−20%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FGHQF calculated?
We run Frontage Holdings Corporation through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1400, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Frontage Holdings Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Frontage Holdings Corporation (FGHQF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.1750. Our model-based fair value is $0.1400, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Frontage Holdings Corporation right now?
Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Frontage Holdings Corporation
How large is the market capitalisation of Frontage Holdings Corporation (FGHQF)?
The market capitalisation of Frontage Holdings Corporation is $355M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Frontage Holdings Corporation (FGHQF)?
The price-to-sales ratio of Frontage Holdings Corporation is 0.87 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Frontage Holdings Corporation (FGHQF)?
The net margin of Frontage Holdings Corporation is 2.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Frontage Holdings Corporation (FGHQF)?
The return on equity (ROE) of Frontage Holdings Corporation is 2.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Frontage Holdings Corporation (FGHQF)?
On an EBIT basis the return on assets of Frontage Holdings Corporation is 3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Frontage Holdings Corporation (FGHQF)?
The operating margin of Frontage Holdings Corporation is 6.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Frontage Holdings Corporation (FGHQF)?
Revenue at Frontage Holdings Corporation is growing +2.9% versus a year earlier (3y avg +0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Frontage Holdings Corporation (FGHQF)?
Earnings per share at Frontage Holdings Corporation are growing +324% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Frontage Holdings Corporation (FGHQF) carry?
The net debt of Frontage Holdings Corporation is $90.6M (fiscal year 2025, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Frontage Holdings Corporation in the live analysis
One click puts Frontage Holdings Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026